Final Program - ILSI BIOMED ISRAEL
• Day 1 - Tuesday, June 05, 2007
• Day 2 - Wednesday, June 06, 2007
• Day 3 - Thursday, June 07, 2007
Tuesday, June 05, 2007
| 09:00 - 09:30
| David Intercontinental, Hall B |
OPENING CEREMONY
|
|
| Chairpersons: | R. Hofstein , Israel | | | R. Arnon , Israel |
|
|
|
WELCOME:
E. Yishai, Minister of Industry, Trade and Labor, Israel
R. Alon, Chairperson, ILSI (Israel Life Science Industry), Israel
D. Zajfman, President, The Weizmann Institute of Science, Israel
S. Mor-Yosef, Director General, Hadassah University Hospital, Israel
|
| 09:30 - 10:15
| David Intercontinental, Hall B |
|
KEYNOTE LECTURE
|
|
Chairperson: D. Zipori, Israel |
|
|
NORMAL AND NEOPLASTIC STEM CELLS
I. Weissman 1 1 Stem Cell Inc., Standford University School Of Medicine, USA
|
|
10:15 |
COFFEE BREAK |
Parallel Session
| 10:45 - 12:45
| David Intercontinental, Hall A |
|
VACCINE DEVELOPMENT AND IMMUNOTHERAPY
|
|
| Chairpersons: | R. Arnon , Israel | | | O. Dar , Israel |
|
|
|
TECHNOLOGIES FOR DEVELOPING NEW VACCINES
R.W. Ellis 1 1 AVANT Pharmaceutics, USA
|
|
|
T CELL VACCINATION THERAPY FOR AUTOIMMUNE DISEASE
I. Cohen 1 1 Weizmann Institute, Rehovot, Israel
|
|
|
THE ROLE OF DELIVERY SYSTEMS AND IMMUNOMODULATORS IN THE PERFORMANCE OF NEW GENERATION INFLUENZA VACCINE
Y. Barenholz 1,2, I. Babai 1, A. Joseph 1, S. Samira 2, J. Spira 2, O. Flasterstein 1, E. Kedar 1 1 Hebrew University Hadassah Medical School; 2 Nasvax, Nes Ziona Israel
|
| 11:45 - 12:45
| David Intercontinental, Hall A |
|
COMPANY PRESENTATIONS
|
|
|
BIOMIMIC PHARMA: NOVEL APPROACHES FOR CANCER IMMUNE THERAPY-TARGETING CELLULAR RESPONSES BY RECOMBINANT ANTIBODIES
Y. Reiter 1, M. Peled Kamar 1 1 Chief Scientist, Faculty Of Biology, Technion-Israel Institute Of Technology, Haifa, And Applied Immune Technologies (AIT) Ltd. Haifa
|
|
|
BIONDVAX: EPITOPE-BASED VACCINE AGAINST INFLUENZA INCLUDING H5N1 AVIAN STRAIN.
E. Ilovitz 1, M. Morozov 1, S. Ziv 1, A. Levakov 1, Y. Levi 1, Y. Adar 2, Y. Singer 1, R. Levi 1, R. Arnon 2, T. Ben-Yedidia 1 1 BiondVax Pharmaceuticals Ltd., Ness Ziona , Israel; 2 Weizmann Institute Of Science, Rehovot, Israel
|
|
|
CURETECH: HARNESSING THE IMMUNE SYSTEM TO COMBAT CANCER
R. Rotem-Yehudar 1 1 V.P., CureTech Ltd., Yavne, Israel
|
|
|
PROTAB LTD: ACTIVE AND PASSIVE VACCINATION FOR RHEUMATOID ARTHRITIS AND TYPE-1 DIABETES WITH A HEAT SHOCK PROTEIN EPITOPE
Y. Naparstek 1, R. Ulmansky 1, S. Yair 1, A. Hershko 1, E. Moallem 1 1 Chief Scientist, ProtAb Ltd. / Jerusalem, Israel
|
|
|
TEVA PHARMACEUTICAL LTD.
O. Ohne 1 1 Manager, Discovery & Research Leader, Teva Ltd., Israel
|
Parallel Session
| 10:45 - 11:45
| David Intercontinental, Hall B |
|
SYMPOSIUM: FDA TODAY
Sponsored by: BECKER & ASSOCIATES CONSULTING, USA
|
|
|
AN EXPERT SYMPOSIUM FOR SCIENTISTS, VENTURE INVESTORS AND CORPORATE EXECUTIVES SEEKING FDA APPROVAL OR CLEARANCE
K. Becker, President, Becker & Associates Consulting, USA
R. Ginor, Medical Director, Becker & Associates Consulting, USA
P.Phillips, Director, Medical Device Practice, Becker & Associates Consulting, USA
M. Heller, Partner and Chair of FDA Group, Goodwin Procter, USA
|
Parallel Session
| 10:45 - 12:45
| David Intercontinental, Hall C |
|
ENTREPRENEURSHIP
|
|
| Chairpersons: | R. Bendori , Israel | | | L. Avitov , Israel |
|
|
|
Speakers:
D. Hefetz, TransPharma, Israel
D. Tolkowsky, TransPharma, Israel
E. Geller, Medica Venture Partners, Israel
N. Nimrodi, Proneuron, Israel
R. Bendori, Evergreen Venture Partners, Israel
L. Avitov, Ofer Hi-Tech, Israel
B. Ahrens, Canaan Partners, USA
|
|
12:45 |
LUNCH BREAK |
| 13:45 - 14:45
| David Intercontinental, Hall B |
|
KEYNOTE LECTURE
|
|
Chairperson: R. Hofstein, Israel |
|
|
BIOTECHNOLOGY FROM A PFIZER PERSPECTIVE: EVOLUTION FOR DEVELOPING BIOTECHNOLOGY ALLIANCES
M. Berelowitz 1 1 Pfizer Inc. USA
|
|
14:45 |
COFFEE BREAK |
Parallel Session
| 15:15 - 17:15
| David Intercontinental, Hall A |
|
ORTHOPEDICS
|
|
Chairperson: M. Liebergall, Israel |
| 16:15 - 17:15
| David Intercontinental, Hall A |
|
COMPANY PRESENTATIONS
|
|
|
CORE DYNAMICS: MAINTAINING VIABILITY OF OSTEOCHONDRAL ALLOGRAFTS FOR TRANSPLANTATION USING DIRECTIONAL FREEZING - 1 YEAR FOLLOW-UP CLINICAL RESULTS
A. Bakay 1, Z. Csernátony 2, L. Csönge 3, S. Norman 4, M. Salai 5 1 Szolnok/HU; 2 Debrecen/HU; 3 Gyor/HU; 4 VP, Orthopedics And Organ Preservation, Core Dynamics, Ness Ziona/IL; 5 Petach-Tikva/IL
|
|
|
IMPLIANT LTD.: IMPLIANT'S MOTION PRESERVATION ALTERNATIVE TO RIGID SPINAL FUSION SURGERY
R. Sacher 1 1 CEO, Impliant Ltd., USA
|
|
|
MAZOR: MAZOR SURGICAL TECHNOLOGIES PRESENTS EFFICACY STUDY RESULTS AND ANNOUNCES THE COMPLETION OF THE 300TH SURGERY WITH THE SPINEASSIST
O. Hadomi 1 1 CEO, Mazor Surgical Technologies, Caesarea, Israel
|
|
|
THE HEBREW UNIVERSITY OF JERUSALEM/HADASSAH UNIVERSITY MEDICAL CENTER: AUGMENTED REALITY GUIDANCE PROBE FOR IMAGE-GUIDED SURGICAL NAVIGATION
R. Shamir 1, L. Joskowicz 1, Y. Shoshan 2 1 School of Eng. and Computer Science, The Hebrew University of Jerusalem; 2 Dept of Neurosurgery, School of Medicine, Hadassah University Medical Center
|
Parallel Session
| 15:15 - 16:15
| David Intercontinental, Hall B |
|
OHIO MEDICAL FACILITIES
|
|
Chairperson: H. Gudell, USA |
|
|
AN OVERVIEW OF OHIO'S GLOBAL CENTER OF EXCELLENCE FOR HEALTHCARE DELIVERY, RESEARCH AND MEDICAL EDUCATION
M. S. Penn, MD, PhD, Director, Bakken Heart-Brain Institute, The Cleveland Clinic, USA
J. M. Dougherty, MD, Chairman, Research and Medical Education, Akron General Medical Center, USA
W. E. Horton, Jr., PhD, Vice President for Research, Northeastern Ohio Universities Colleges of Medicine and Pharmacy, USA
C. M. Croce, MD, Director, Ohio State University Medical Center, Comprehensive Cancer Center, USA
W. L. Poll, MD, Innovation Consultant, Ohio Health Corporation, USA
|
Parallel Session
| 15:15 - 17:15
| David Intercontinental, Hall C |
|
AESTHETIC DERMATOLOGY
|
|
Chairperson: A. Reiter, Israel |
|
|
ENERGY BASED SYSTEMS FOR AESTHETIC DERMATOLOGY
M.H. Gold 1,2,3,4 1 Medical Director, Gold Skin Care Center, Nashville, TN USA; 2 Medical Director, Tennessee Clinical Research Center, Nashville, TN USA; 3 Clinical Assistant Professor, Dermatology, Vanderbilt University School of Medicine and School of Nursing, Nashville, TN USA; 4 Visiting Professor of Dermatology, Huashan Hospital, Fudan University, Shanghai, China
|
|
|
THE AESTHETIC INDUSTRY: BUSINESS TRENDS AND OPPORTUNITIES
A. Tenstam 1 1 ColBar Life Science Ltd, UK
|
| 16:15 - 17:15
| David Intercontinental, Hall C |
|
COMPANY PRESENTATIONS
|
|
|
IMPLITE LTD.
A. Glicksman 1 1 CEO, Implite Ltd.
|
|
|
RADIANCY
|
|
|
SYNRON
D. Gerstel 1 1 President Of Syneron North America, Synron, USA
|
|
|
ULTRASHAPE LTD.: THE SHAPE OF THINGS TO COME
R.L. Stewart 1 1 President & CEO, UltraShape, Inc.,Yoqneam, Israel
|
| 17:15 - 18:15
| David Intercontinental, Hall B |
|
SPECIAL LECTURE: THE GLOBAL ANGLE OF BIOBUSINESS
Sponsored by: BiolineRX
|
|
Chairperson: M. Laster, Israel |
|
SATELLITE SESSION: TUESDAY, JUNE 05, 2007
By Invitation Only
|
|
12:30 |
PUBLISHING SCIENTIFIC FACTS AND CONCEPTS
1 Yissum Technology Transfer
|
Back to top Wednesday, June 06, 2007
| 09:00 - 09:40
| David Intercontinental, Hall B |
|
KEYNOTE LECTURE
|
|
Chairperson: T. Howson, USA |
|
|
GREETINGS
E. Opper 1 1 The Chief Scientist, Ministry Of Industry, Trade And Labor, Israel
|
|
|
HOW TO PLAY ON THE GLOBAL ARENA
J. Karabelas 1 1 Care Capital, USA
|
| 09:40 - 10:20
| David Intercontinental, Hall B |
|
KEYNOTE LECTURES
|
|
Chairperson: Y. G. Weiss, Israel |
|
|
STRATEGIES FOR EARLY DRUG DISCOVERY AT MERCK RESEARCH LABORATORIES
B. Strulovici 1 1 Merck & Co, USA
|
|
|
DISCOVERY OF BIOLOGICAL PROBES & DRUG-LIKE LEADS THROUGH HIGH-THROUGHPUT SCREENING TECHNOLOGIES: CASE STUDIES FROM SCRIPPS FLORIDA
P. Hodder 1 1 Scripps Florida, USA
|
|
10:20 |
COFFEE BREAK |
Parallel Session
| 10:45 - 11:45
| David Intercontinental, Hall B |
|
PERSONALIZED MEDICINE
|
|
| Chairpersons: | Y. Weiss , Israel | | | Y. Koltin , USA |
|
|
|
GENETICS AND GENOMICS IN CLINICAL MEDICINE
R. Kucherlapati 1 1 Harvard University, USA
|
|
|
PERSONALIZED MEDICINE - THE PROMISE AND THE REALITY
M.G. Aspinall 1 1 Genzyme Genetics, USA
|
|
|
TITLE TO BE ADVISED
G. Rechavi 1 1 The Sheba Cancer, Israel
|
| 11:45 - 12:45
| David Intercontinental, Hall B |
|
COMPANY PRESENTATIONS
|
|
|
COMPUGEN: GENEVA™, A PLATFORM FOR THE DETECTION OF NON-SNP SEQUENCE VARIATION IN THE HUMAN GENOME, DETECTS A POTENTIAL NOVEL SUSCEPTIBILITY VARIATION IN TYPE II DIABETES
A. Vaknin 1, R. Shemesh 1, A. Toporik 1, Z. Levine 1, S. Pollock 1, A. Rosenberg 1, A. Wool 1, M. Ayalon-Soffer 1, P. Akiva 1, E.Y. Levanon 1, T. Zekharya 1, S. Edelheit 1, L. Bazak 1, A. Gulobev 1, Y. Kliger 1, A. Amir 1, Y. Cohen 1 1 V.P R&D, Compugen, Tel-Aviv, Israel
|
|
|
LINKAGENE: A DIFFERENT APPROACH TO PERSONALIZED MEDICINE
S.G. Kachalsky 1, G. Horev 2, P. Haak 2, P. Norton 2, J. Resau 2, E. Kerem 3 1 LINKAGENE LTD. , c/o Spark Enterprise Venture Fund, P.O.Box: 73, Lod, Israel; 2 The Van Andel Research Institute, Grand Rapids, MI. USA; 3 The Mount Scopus Hadassah Hospital, Jerusalem, Israel
|
|
|
ROSETTA GENOMICS: NOVEL DIAGNOSTICS AND THERAPEUTICS BASED ON MICRORNAS
A. Avniel 1 1 Rosetta Genomics, Israel
|
|
|
OPTIMATA: NOVEL VIRTUAL PATIENT TECHNOLOGY FOR OPTIMIZING ONCOLOGY CLINICAL DEVELOPMENT AND REDIRECTING DISCONTINUED ONCOLOGY COMPOUNDS TOWARDS A MORE PROMISING DEVELOPMENT PATHWAY
G.C. Malchi 1, Z. Agur 1 1 CEO, Optimata Ltd., Ramat Gan, Israel; 2 Imbm, Bney Atarot, Israel
|
Parallel Session
| 10:45 - 12:45
| David Intercontinental, Hall C |
|
INTERVENTIONAL CARDIOLOGY
|
|
| Chairpersons: | R. Beyar , Israel | | | A. Molcho , Israel |
|
|
|
DRIVING INTERNAL INNOVATION
C.D. Rogers 1 1 Research & Development, Cordis Corporation, Warren, New Jersey, USA
|
|
|
STRUCTURAL HEART DISEASE AND HEART FAILURE IN INTERVENTIONAL CARDIOLOGY
G. Keren 1 1 Tel Aviv Medical Center, Israel
|
| 11:45 - 12:45
| David Intercontinental, Hall C |
|
COMPANY PRESENTATIONS
|
|
|
ATRIA MEDICAL INC.
T. Harel 1 1 Atria Medical Inc., Israel
|
|
|
BIOLINERX: INTRA_CORONARY INJECTION OF BL-1040 MYOCARDIAL IMPLANT IMPROVES CARDIAC FUNCTION AND DECREASES REMODELLING AFTER ACUTE MYOCARDIAL INFARCTION
S Tuvia 1, M.C Laster 2, K Savitsky 1, H Ron 1, L Klapper 1, M Shaul 1, S Jencmen 1, I Winkler 1, S Cohen 3, J Leor 4 1 Project Manager, Bioline Innovations Jerusalem, LP, Jerusalem, Israel; 2 BioLineRx, Jerusalem, Israel; 3 Department of Biotechnology, Faculty of Engineering Science, Ben-Gurion University of the Negev, Beer-Sheva, Israel; 4 Neufeld Cardiac Research Institute, TAU, Sheba Medical Center, Israel
|
|
|
CAPELLA: SIDEGUARD TECHNOLOGY - A NEW WAY OF TREATING COMPLEX LESIONS
Guy Neev 1 1 CEO, Cappella Inc., Israel
|
|
|
NEUROSONIX LTD.
N. Sela 1 1 CEO, Neurosonix Ltd., Israel
|
|
12:45 |
LUNCH BREAK |
| 13:45 - 14:45
| David Intercontinental, Hall B |
|
KEYNOTE LECTURE
|
|
Chairperson: O. Abramsky, Israel |
|
|
VACCINATION THERAPY FOR ALZHEIMER'S DISEASE: THE PROMISE AND THE PROBLEM
R. Rosenberg 1 1 Dept. Of Neurology, University Of Texas Southwestern Medical Center, Dallas, USA
|
|
14:45 |
COFFEE BREAK |
Parallel Session
| 15:15 - 16:15
| David Intercontinental, Hall B |
|
METABOLIC DISORDERS
|
|
Chairperson: R. Alon, Israel |
| 16:15 - 17:15
| David Intercontinental, Hall B |
|
COMPANY PRESENTATIONS
|
|
|
BETA-02 TECHNOLOGIES: NEW TREATMENT FOR DIABETES TYPE I
C.A. Schneider 1 1 CEO, Beta-O2 Technologies Ltd., Israel
|
|
|
HEALOR LTD: INNOVATIVE APPROACH TO WOUND HEALING CARE
T. Tennenbaum 1, I. Solominik 1, E. Brener 1, M. Ben Hamo 1, O. Levy-Hacham 1, E. Braude 1, L. Braiman-Wiksman 1 1 CEO, HealOr Ltd., Ness Ziona, Israel
|
|
|
OBECURE LTD: OBE101 - A NOVEL THERAPEUTIC APPROACH TO WEIGHT MANAGEMENT
N. Barak 1, Y. Eyal 1, Y. Beck 1 1 CEO, Obecure Ltd., Israel
|
|
|
SPATZ-FGIA LTD: THIRD GENERATION INTRAGASTRIC BALLOON FOR OBESITY WITH BUILT-IN ANCHOR AND UNLIMITED ADJUSTABLE INFLATION TUBING
J.S. Brooks 1 1 Chairman And CSO, Spatz-FGIA Ltd, Raanana, Israel
|
|
|
THE ENDOCRINE INSTITUTE SHEBA MEDICAL CENTRE: USING ADULT TISSUES TO GENERATE NEW ORGANS: AUTOLOGOUS CELL REPLACEMENT THERAPY FOR DIABETES
S. Ferber 1-3, T. Sapir 3, K. Ron 1, I. Meivar-Levy 1 1 Endocrine Institute, Sheba Medical Ctr. Tel-Hashomer, Israel; 2 Human Genetics, Sackler School Of Medicine, TAU, TA, Israel; 3 Surgery, DRI, Miller School Of Medicine, U Of Miami, Miami FL, USA; 4 Bar-Ilan University, Ramat-Gan Israel
|
Parallel Session
| 15:15 - 17:15
| David Intercontinental, Hall C |
|
CANCER
|
|
| Chairpersons: | D. Haratz , Israel | | | G. Rehavi , Israel |
|
|
|
ROLE OF MICRO RNAS' IN CANCER
G.M. Croce 1 1 Texas State University, USA
|
|
|
BUILDING LIFE SCIENCES COMPANIES IN THE GLOBAL ENVIRONMENT
J. Holaday 1,2 1 QRxPharma, Sydney, Australia; 2 Department of Anesthesiology and Critical Care/the Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
|
|
|
RNA INTERFERENCE AS A RESEARCH AND THREAPEUTIC TOOL
S. Izraeli 1 1 Head, Research section, Pediatric Hemato-Oncology, Cancer Research Center, Sheba Medical Center, Tel-Hashomer, Ramat Gan, Israel
|
| 16:15 - 17:15
| David Intercontinental, Hall C |
|
COMPANY PRESENTATIONS
|
|
|
BIOCANCELL THERAPEUTICS: A NOVEL PERSONALIZED MEDICINE APPROACH FOR SOLID TUMORS
A. Hochberg 1, A. Barak 1 Founder, Chairman Of The Board And CSO Of BioCancell Therapeutics, Inc., Israel
|
|
|
GAMMACAN INTERNATIONAL INC: VITIGAM™ AN IGG-BASED PRODUCT FROM DONORS WITH VITILIGO TO TREATMALIGNANT MELANOMA
J. Nusbacher 1, P.N.J. Schnegelsberg 1, Y. Shoenfeld 2 1 GammaCan International Inc.; 2 Tel Aviv University; 3 Chaim Sheba Medical Center
|
|
|
GAMIDA CELL: STEM CELL EXPANSION TECHNOLOGIES AND THE CLINICAL APPLICATIONS
Y. Margolin 1, Y. Daniely 1, F. Grynspan 1 1 CEO, Gamida Cell Ltd., Israel
|
|
|
VBL
E. Breitbart 1 1 VBL, Israel
|
| 17:15 - 18:45
| David Intercontinental, Hall B |
|
PANEL: ILSI'S PARADE OF THE BIOMED INDUSTRY IN ISRAEL
|
|
Chairperson: G. Weinreb, Israel |
|
|
E. Opper, Office of the Chief Scientist, Israel
R. Alon, Pitango Venture Capital, Israel
A. Koren, G.C.P. Israel
A. Schwartz, Teva Pharmaceutical Industries Ltd, Israel
D. Vilenski, Applied Materials, Israel
L. Recanati, Glenrock, Israel
Z. Zelig, Genzyme, Israel
|
| 18:45 - 19:15
| David Intercontinental, Hall B |
|
RAD BIOMED AWARD CEREMONY
|
Back to top Thursday, June 07, 2007
| 09:00 - 09:30
| David Intercontinental, Hall B |
|
KEYNOTE LECTURE
|
|
Chairperson: R. Hofstein, Israel |
|
|
TITLE TO BE ADVISED
M. Tanner 1 1 Life Science Partners, NY, USA
|
| 09:30 - 10:20
| David Intercontinental, Hall B |
|
PLENARY: ISRAELI BIOMED GOES PUBLIC
|
|
| Chairpersons: | O. Shahaf , Israel | | | T. Sultan , Israel |
|
| 10:40 - 12:00
| David Intercontinental, Hall C |
|
GLOBAL STATUS: ASIA
Sponsored by: REINHOLD COHN
|
|
Chairperson: I. Cohn, Israel |
|
|
OPENING REMARKS
I. Cohn 1 1 Head Of The Life Science Group, Reinhold Cohn Group, Israel
|
|
|
CHALLENGES & OPPORTUNITIES IN INDIA
D. Followwill 1 1 Manager Of Healthcare EMEA & APAC, Frost & Sullivan, USA
|
|
|
CHALLENGES & OPPORTUNITIES IN CHINA
G. Chan 1 1 Managing Director, Morningside Technology, Hong Kong
|
|
|
PHARMACEUTICAL & MEDICAL DEVICE BUSINESS IN CHINA
K.Y. Cheong 1 1 Senior Vice President, Transpac Capital ,Singapore
|
|
|
OPPORTUNITIES IN SINGAPORE
L. Chan 1 1 Chief Executive Officer, NUS Enterprise, Singapore
|
|
|
Q&A SESSION
|
| 10:40 - 12:00
| David Intercontinental, Hall B |
|
FROM OUR PIPELINE TO YOUR BOTTOM LINE: NEW GROUNDBREAKING TECHNOLOGIES FROM THE WEIZMANN INSTITUTE OF SCIENCE
Sponsored by: YEDA R&D CO. LTD
|
|
Chairperson: A. Naiberg, Israel |
|
|
HIGH-RESOLUTION, HIGH-FIDELITY, COST-EFFECTIVE DIAGNOSTIC ALTERNATIVE TO DNA HYBRIDIZATION AND SEQUENCING (P.I. – PROF. J. STAVANS)
S. Marcus 1 1 Yeda Business Development Dept., Israel
|
|
|
ANTI-PROLIFERATIVE INTERFERON MUTANTS WITH PRONOUNCED ANTI-CANCER ACTIVITY (P.I. - PROF. G. SCHREIBER)
E. Zisman 1 1 Yeda Business Development Dept, Israel
|
|
|
MRI-BASED CANCER DIAGNOSIS METHODS WITH IMPROVED ACCURACY (P.I. - PROF. H. DEGANI)
S. Marcus 1 1 Yeda Business Development Dept., Israel
|
|
|
NEW REAGENTS FOR MRI BASED CANCER DIAGNOSIS (P.I. – PROF. M. NEEMAN)
E. Zisman 1 1 Yeda Business Development Dept, Israel
|
|
|
AUTOMATIC SEGMENTATION OF CT AND MR IMAGES (P.I. – PROF. RONEN BASRI)
S. Marcus 1 1 Yeda Business Development Department, Israel
|
|
12:00 |
LUNCH BREAK |
Parallel Session
| 13:00 - 14:00
| David Intercontinental, Hall B |
|
GLOBAL STATUS: EUROPE
Supported by: EUROPEAN COMMISSION
|
|
| Chairpersons: | S. Hogan , Belgium | | | J. Hodgson , Belgium |
|
|
|
SUPPORTABLE VENTURES IN EUROPE
W. Brooks 1 1 Senior Investment Manager Life Sciences, Quest Management, Belgium
|
|
|
TITLE TO BE ADVISED
A. Fraser 1 1 Partner, 3i, Denmark
|
|
|
PANORAMA OF SITUATION FOR THE BIOTECH INDUSTRY IN EUROPE
M. Leader 1 1 Healthcare Council Director, EuropaBio
|
Parallel Session
| 13:00 - 14:00
| David Intercontinental, Hall C |
|
PROJECT PRESENTATIONS:
Sponsored by: YISSUM TECHNOLOGY TRANSFER
|
|
Chairperson: N. Swersky Sofer, Israel |
|
|
CONVERSION OF PEPTIDES INTO ORALLY AVAILABLE AND BBB PERMEABLE DRUG LEAD USING THE BACKBONE CYCLIZATIOM AND CYCLOSCAN TECHNOLOGIES
G. Gilon 1, Y. Linde 1, S. Hess 2, O. Ovadia 2, E. Safrai 3, T. Lapidot 4, I. Winkler 4, A. Faier 4, D. Yarden 4, C. Haskell-Luevano 5, D.E. Shalev 3, A. Hoffman 2 1 Departments Of Organic Chemistry, The Hebrew University Of Jerusalem, Israel; 2 Departments of Pharmaceutics, The Hebrew University of Jerusalem; 3 Wolfson Center of Applied Structural Biology, The Hebrew University of Jerusalem; 4 Bioline Innovations, Jerusalem, Israel; 5 and the Department of Medicinal Chemistry, University of Florida, Gainesville, Florida, USA
|
|
|
REGULATION OF OXIDATIVE STRESS – KEY TO NEW THERAPEUTICS
A. Haj-Yehia 1, M. Pharm 1 1 Yissum Technology Transfer Company, Israel
|
|
|
ORAL ADMINISTRATION OF A NOVEL PEPTIDE – A POTENTIAL TREATMENT OF AUTOIMMUNE DISEASES
U. Wormser 1, E. Shapira 1, A. Rosengarten 1, B. Brodsky 1 1 Department of Pharmacology, School of Pharmacy, Faculty of Medicine, The Hebrew University, Jerusalem, Israel
|
|
|
DEPRESSION INDUCES BONE LOSS VIA STIMULATION OF THE SYMPATHETIC NERVOUS SYSTEM.
I. Bab 1 1 Bone Laboratory, The Hebrew University of Jerusalem, Jerusalem
|
|
|
A NOVEL METHOD FOR NAVIGATING IN THE CORONARY ARTERIES AND HEART CHAMBERS DURING DIAGNOSTIC AND THERAPEUTIC PROCEDURES
Y. Smith 1 1 Hebrew University, Jerusalem, Israel
|
Parallel Session
| 14:00 - 15:30
| David Intercontinental, Hall B |
|
GLOBAL STATUS: USA
|
|
Chairperson: M. Tanner, USA |
|
|
Speakers:
J. Fleming, Oxford Bioscience Partners, USA
J. Silverstein, Orbimed Venture Found, USA
T. Howson, Lexicon Pharmaceuticals, USA
J. Levin, Novartis, USA
|
| 14:00 - 15:30
| David Intercontinental, Hall C |
|
PROJECT PRESENTATIONS: TECHNION - ISRAEL INSTITUTE OF TECHNOLOGY
|
|
Chairperson: B. Soffer, Israel |
|
|
SEALANTIS, A BIOMIMETIC ADHESIVE
H. Bianco-Peled 1 1 Technion R&D Foundation, Haifa, Israel
|
|
|
A NEW CARDIOPROTECTIVE DRUG
O. Binah 1 1 Technion R&D Foundation, Haifa, Israel
|
|
|
HIGH INTENSITY FOCUSED ULTRASOUND (HIFU) - THE SURGEON KNIFE OF THE FUTURE
H. Azhari 1 1 Technion R&D Foundation, Haifa, Israel
|
| 08:30 - 18:00
| No Room Allocated |
|
SATELLITE SESSIONS: THURSDAY, JUNE 7, 2007
By Invitation Only
|
|
13:00 |
ENCOURAGING ACADEMIA - INDUSTRY COLLABORATION
1 ITTN (Israel Technology Transfer Organization
|
|
08:30 |
ITALY-ISRAEL SEMINAR AND NETWORKING EVENT
|
|
14:15 |
ITALY-ISRAEL SEMINAR AND NETWORKING EVENT
|
Back to top
|
